YUMAB develops therapeutic antibodies for clients and partners using one of world’s largest human antibody libraries (>10e11), patient derived libraries or immune libraries.
YUMAB's integrated discovery and engineering platform offers highest success-rates to all types of antigens including “difficult” targets such as GPCRs, transporters or ion channels.
YUMAB provides all technologies from target to optimized lead in one hand. Technologies include fast track in vitro antibody selection and screening (including on cell selection), antibody engineering (including superhumanization) and bioinformatic lead optimization.
Newest achievement is the fast track COVID-19 program of YUMAB's spin-off CORAT Therapeutics from target to patient in 11 months.
YUMAB® Antibody Library Features
- Natural antibody repertoires (no synthetic sequences)
- Universal and broad repertoire (all human frame works and CDR lengths)
- Large epitope coverage and high hit rate
- Flexible business conditions
YUMAB® Antibody discovery technologies.
- The power of in-vitro antibody selection.
- Challenging difficult targets by optimized discovery solutions.
- From target to lead.
YUMAB® humanization platform:
- Germline-optimized CDR grafting
- Template-driven chain shuffling
Fast track development of SARS-CoV-2 antibody (6 months).
In less than six months, an antibody gene library was generated, screened against SARS-CoV-2 S1 protein and a fi nal lead molecule (COR-101) was identifi ed by a set of selected assays including life virus neutralization and CMC assessment YUMAB‘s antibody discovery and development platform identifi ed several promising candidates with high affi nity, very good developability prediction and binding to most presently known SARS-CoV-2 variants.
Antibodies expressed at GMP standards after stable cell line development show a high expression titer and exhibit good developability.